Condition
Initially Unresectable
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Combination Of Gemcitabine Nabpaclitaxel Sintilimab And Bevacizumab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05757336Phase 2Recruiting
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT04984980Phase 2Unknown
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Showing all 2 trials
Research Network
Common Treatments
- Combination Of Gemcitabine Nabpaclitaxel Sintilimab And Bevacizumab1
- Combination Of Gemcitabine Oxaliplatin Sintilimab And Bevacizumab1
Active Sponsors
- Fudan University1
- Lu Wang, MD, PhD1
Related Conditions
- Biliary Tract Carcinoma1
- Gallbladder Cancer1
- The First Line Treatment1